Bienville Capital Management, LLC Biogen Inc. Transaction History

Bienville Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$264.77 - $305.71 $311,104 - $359,209	-1,175 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$258.66 - $342.55 $303,925 - $402,496	1,175 New	1,175 $314,000
Q3 2019 Nov 14, 2019	SELL	$217.44 - $243.88 $333,987 - $374,599	-1,536 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$219.29 - $241.72 $43,419 - $47,860	198 Added 14.8%	1,536 $359,000
Q1 2019 May 13, 2019	SELL	$216.71 - $338.96 $1,950 - $3,050	-9 Reduced 0.67%	1,338 $316,000
Q4 2018 Feb 13, 2019	BUY	$278.5 - $352.75 $375,139 - $475,154	1,347 New	1,347 $405,000
Q1 2018 May 15, 2018	SELL	$260.13 - $367.91 $247,643 - $350,250	-952 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $22,150 - $24,809	72 Added 8.18%	952 $303,000
Q3 2017 Nov 14, 2017	BUY	$281.15 - $329.69 $247,411 - $290,127	880	880 $276,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Bienville Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bienville Capital Management, LLC with notifications on news.